CD274 and cancer: According to Sivan et al. the difference in the gut microbiota composition, particularly Bifidobacterium, influences anti-cancer immunity and the therapeutic efficacy of anti-PDL1 therapy by altering DC maturation and tumor-specific T cell response [162].